The dopamine receptor D2 agonist bromocriptine inhibits glucose-stimulated insulin secretion by direct activation of the alpha2-adrenergic receptors in beta cells.

de Leeuw van Weenen, J E; Parlevliet, E T; Maechler, P; Havekes, L M; Romijn, J A; Ouwens, D M; Pijl, H; Guigas, B

de Leeuw van Weenen, J E; Parlevliet, E T; Maechler, P; Havekes, L M; Romijn, J A; Ouwens, D M; Pijl, H; Guigas, B.

Affiliation

de Leeuw van Weenen JE; Department of Endocrinology and Metabolic Diseases, Leiden University Medical Center, Leiden, The Netherlands. j.e.de_leeuw@lumc.nl

Biochem Pharmacol ; 79(12): 1827-36, 2010 Jun 15.

Article in En | MEDLINE | ID: mdl-20138024

Subject(s)

Bromocriptine/pharmacology; Dopamine Agonists/pharmacology; Insulin-Secreting Cells/drug effects; Insulin/metabolism; Receptors, Adrenergic, alpha/metabolism; Receptors, Dopamine D2/agonists; Animals; Cell Line; Dose-Response Relationship, Drug; Glucose/pharmacology; Insulin Secretion; Insulin-Secreting Cells/metabolism; Insulinoma; Male; Mice; Mice, Inbred C57BL; Rats

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Bromocriptine / Receptors, Adrenergic, alpha / Receptors, Dopamine D2 / Dopamine Agonists / Insulin-Secreting Cells / Insulin Limits: Animals Language: En Journal: Biochem Pharmacol Year: 2010 Document type: Article Affiliation country: Netherlands

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google